secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2022-11-18T23:59:59+00:00
Accession:  0001297184-22-000060
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar subsidiary enters up to $1.5M supply deal with related party Letop Biotech
--------------------------------------------------------------------------------

- ANP subsidiary signed 3-year supply agreement with Nanjing Letop Biotechnology for chemical intermediates.
- Total cost capped at ~$1.5M over 3 years; no minimum purchase obligation for ANP.
- Henry Zhang, immediate family of CEO Jack Zhang and Chair Mary Luo, owns majority of Letop; deal was approved by independent Audit Committee members.
- ANP retains ownership of all confidential information shared with Letop under the agreement.
- Payments in Chinese yuan; price adjustments allowed once per 12 months with 2-month notice and customer consent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000060/0001297184-22-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000060/amph-20221115x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-22-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer